2026 年至 2032 年格林-巴利綜合症藥物市場（按治療類型、藥物類別、分銷管道和地區分類）

格林巴利症候群治療市場評估 - 2026-2032

免疫療法的進步和對罕見神經系統疾病的認知不斷提高推動了格林-巴利綜合症 (GBS) 治療市場的發展。分析師估計，格林巴利症候群治療市場規模將從 2024 年的 12 億美元成長到 2032 年的 20.9 億美元。

格林-巴利綜合症藥物市場的快速擴張主要歸因於全球格林-巴利綜合症發病率的增加、診斷能力的提高以及對新治療方法研發的投資增加。這些因素將推動市場在 2026 年至 2032 年期間以 7.20% 的複合年成長率成長。

格林-巴利綜合症藥物市場定義/概述

格林巴利症候群是一種罕見的神經系統疾病，患者免疫系統會錯誤地攻擊部分周邊神經系統。這會導致肌肉迅速無力，甚至癱瘓。 GBS 藥物市場包括用於治療和控制該疾病症狀的藥物。

此外，格林-巴利綜合症的主要治療方法集中在減少免疫系統對神經系統的攻擊並支持患者的康復過程。這通常涉及免疫球蛋白、血漿置換和支持性治療。此外，還有各種藥物可用於治療格林-巴利症候群常伴隨的某些症狀，如疼痛、疲勞和憂鬱。

推動格林-巴利綜合症治療市場成長的關鍵因素有哪些？

全球範圍內格林-巴利綜合症發病率的不斷上升是尋求更好治療方法的主要動力。世界衛生組織 (WHO) 估計，格林巴利症候群每年影響每十萬人口中的 1 至 2 人，全球受影響人數總合超過 10 萬人。越來越多的格林巴利症候群患者需要接受免疫球蛋白和血漿置換治療。

免疫球蛋白 (IVIg) 療法已成為治療格林-巴利症候群最有效的方法，其日益普及正在刺激市場擴張。 2020年，美國國立衛生研究院（NIH）宣布，已開發國家超過80%的GBS病例採用IVIg療法治療。這種治療劑的廣泛使用正在推動市場對免疫球蛋白製劑的需求。

此外，用於早期檢測格林巴利症候群的改進的診斷工具和更快的治療可用性正在推動市場的發展。根據歐洲神經學會聯合會（EFNS）的報告，由於電生理測試和腦脊髓液分析的進步，近年來診斷格林-巴利綜合症的準確率提高了70％以上。早期準確的診斷對於有效治療至關重要，從而推動了對格林-巴利綜合症藥物的需求。

影響格林-巴利綜合症治療市場採用的主要挑戰是什麼？

採用藥物治療格林-巴利綜合症面臨多項挑戰，其中之一就是藥物成本高。免疫球蛋白療法是格林-巴利症候群的主要治療方法，由於從人體血漿中獲取免疫球蛋白製劑的製造過程十分複雜，因此費用昂貴。這構成了一個障礙，特別是對於那些無法獲得先進醫療治療的中低收入地區的患者而言。此外，高昂的藥品成本對醫療保健造成壓力，使得這些重要的治療方法難以廣泛普及且價格實惠。

另一個重大挑戰是某些地區有效治療方案有限。免疫球蛋白療法和血漿置換被認為是格林-巴利症候群的標準治療方法，但各國獲得這些藥物的機會並不統一。在醫療基礎設施不發達的地區，這些藥物的短缺和接收藥物的延遲可能會對患者的治療結果產生不利影響。此外，免疫球蛋白也用於治療其他自體免疫疾病和神經系統疾病，導致全球需求增加，並引發影響格林-巴利症候群患者的供應限制。

此外，格林-巴利症候群的診斷很複雜，及時給藥是一項挑戰。格林-巴利綜合症是一種罕見疾病，且進展迅速，因此早期診斷對於有效治療至關重要。但肌肉無力和癱瘓等症狀可能與其他神經系統疾病相似，這使得醫療保健提供者難以診斷。延遲識別格林-巴利綜合症可能會導致錯過及時使用免疫球蛋白或血漿置換治療的機會，從而限制現有治療方式的整體有效性，並可能使患者的預後惡化。這些診斷挑戰也限制了GBS治療在市場上的廣泛使用。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 格林-巴利綜合症藥物的競爭市場（依藥物類別）

• 免疫球蛋白
• 抗驚厥藥
• 抗憂鬱症
• 非類固醇消炎劑
• 鴉片類藥物
• 其他

5. 格林-巴利綜合症藥物的治療類型競爭市場

• 靜脈注射免疫球蛋白治療
• 血漿置換
• 支持治療

6. 格林-巴利綜合症藥物的競爭市場（按分銷管道分類）

• 醫院藥房
• 零售藥局
• 網路藥局

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Grifols SA
• CSL Behring
• Shire（現為武田藥品工業株式會社的子公司）
• Octapharma AG
• Nihon Pharmaceutical Co., Ltd.
• Akari Therapeutics, Plc
• Hansa Biopharma AB
• BIoTest AG
• China Biologic Products Holdings, Inc.
• Kedrion Biopharma Inc.

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Guillain Barre Syndrome Drugs Market Valuation - 2026-2032

The Guillain Barre Syndrome (GBS) drugs market is driven upwards by advancements in immunotherapy and increasing awareness of rare neurological disorders. According to analysts, the GBS drugs market is estimated to reach a valuation of USD 2.09 Billion by 2032, up from USD 1.20 Billion in 2024.

The rapid expansion of the GBS drugs market is primarily driven by the rising global incidence of GBS, improving diagnostic capabilities, and growing investment in research and development of novel therapies. These factors are enabling the market to grow at a CAGR of 7.20 % from 2026 to 2032.

Guillain Barre Syndrome Drugs Market: Definition/Overview

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system. This leads to rapid-onset muscle weakness and, in some cases, paralysis. The GBS drugs market encompasses pharmaceutical products used to treat and manage the symptoms of this condition.

Furthermore, the primary treatments for GBS are focused on reducing the immune system's attack on the nervous system and supporting patients through the recovery process. This is typically achieved using immunoglobulins, plasma exchange, and supportive care. Additionally, various drugs are utilized to manage specific symptoms such as pain, fatigue, and depression that often accompany GBS.

What are the Key Drivers Propelling the Growth of the Guillain Barre Syndrome Drugs Market?

The increased global frequency of Guillain-Barre Syndrome is a primary driving force behind the quest for better treatments. The World Health Organization (WHO) estimates that GBS affects 1 to 2 persons per 100,000 people each year, totaling more than 100,000 cases worldwide. The increasing incidence of GBS cases necessitates treatments such as immunoglobulins and plasmapheresis.

Immunoglobulin (IVIg) therapy has emerged as the most effective treatment for GBS, and its growing popularity is fueling market expansion. In 2020, the National Institutes of Health (NIH) stated that IVIg therapy was used in more than 80% of GBS cases in developed countries. The extensive usage of this treatment is driving up demand for immunoglobulin goods in the market.

Furthermore, improved diagnostic tools for early detection of GBS have led to more prompt delivery of treatments, propelling the market. The European Federation of Neurological Societies (EFNS) reports that advances in electrophysiological testing and cerebrospinal fluid analysis have enhanced GBS diagnostic accuracy by more than 70% in recent years. Early and precise diagnosis is crucial for giving effective therapies, which drives demand for GBS medicines.

What are the Key Challenges Impacting the Adoption of Guillain Barre Syndrome Drugs in the Market?

The adoption of Guillain-Barre Syndrome (GBS) drugs faces several challenges, one of which is the high cost of treatment. Immunoglobulin therapies, which are the primary treatment for GBS, tend to be expensive due to the complex production process involved in deriving these products from human plasma. This creates barriers for patients, especially in low- and middle-income regions, where access to advanced healthcare treatments is limited. The high cost also puts pressure on healthcare systems, making it difficult to ensure the widespread availability and affordability of these critical treatments.

Another significant challenge is the limited availability of effective treatments in certain regions. While immunoglobulin therapies and plasmapheresis are considered the standard of care for GBS, access to these treatments is not uniform across all countries. In regions with underdeveloped healthcare infrastructures, there are shortages of these drugs or delays in treatment, which negatively affect patient outcomes. Additionally, the global demand for immunoglobulins has risen due to their use in other autoimmune and neurological disorders, leading to supply constraints and impacting GBS patients.

Furthermore, the diagnostic complexity of Guillain-Barre Syndrome poses a challenge to timely drug adoption. GBS is a rare and rapidly progressing condition, and early diagnosis is crucial for effective treatment. However, its symptoms-such as muscle weakness and paralysis-mimic other neurological conditions, making diagnosis difficult for healthcare providers. Delays in identifying GBS result in missed opportunities for timely treatment with immunoglobulins or plasmapheresis, limiting the overall efficacy of the available therapies and potentially worsening patient outcomes. These diagnostic challenges also hinder the overall uptake of GBS-specific drugs in the market.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for Intravenous Immunoglobulin?

The intravenous immunoglobulin (IVIG) segment is estimated to dominate the market in the treatment type category during the forecast period. IVIG therapy is widely recognized as a first-line treatment for GBS due to its effectiveness in rapidly modulating the immune response. The ability of IVIG to reduce the severity and duration of GBS symptoms is making it a preferred choice among healthcare providers.

The relatively lower risk profile of IVIG compared to plasma exchange is also contributing to its dominance. IVIG treatment is associated with fewer complications and is generally better tolerated by patients, particularly those who are critically ill or have contraindications to plasma exchange.

Furthermore, the convenience of IVIG administration is noted as a factor driving its preference. The therapy is given in outpatient settings, reducing the need for prolonged hospital stays. This aspect is not only improving patient comfort but also potentially reducing overall treatment costs, making IVIG an attractive option for both patients and healthcare systems.

What are the Potential Factors for the Growth of Immunoglobulins in the Market?

The immunoglobulins segment is estimated to dominate the GBS drugs market in the drug class category during the forecast period. The proven efficacy of immunoglobulins in GBS treatment is the primary driver of this dominance. These drugs are + shown to effectively reduce the immune system's attack on the nervous system, leading to faster recovery and improved outcomes for patients.

The versatility of immunoglobulins in treating various autoimmune and inflammatory conditions is also contributing to their market leadership. The wide range of applications is driving increased production and availability of these drugs, potentially leading to economies of scale and improved accessibility for GBS patients.

Furthermore, ongoing research is conducted into novel formulations and administration methods for immunoglobulins. These innovations are aimed at enhancing efficacy, reducing side effects, and improving patient convenience. Such advancements are expected to further solidify the position of immunoglobulins in the GBS drugs market.

What are the Key Factors that Contribute to North America's Edge in the Market?

According to VMR Analyst, North America is estimated to dominate the Guillain barre syndrome drugs market during the forecast period. The growing prevalence of Guillain-Barre Syndrome in North America significantly drives the demand for effective treatments, including immunoglobulins and plasmapheresis. According to the Centers for Disease Control and Prevention (CDC), GBS affects approximately 3,000 to 6,000 people in the United States each year. The consistently high incidence rate of GBS fosters a robust market for therapies in the region.

The correlation between Zika virus infections and the onset of GBS has contributed to a growing demand for treatment options. In 2016, the CDC reported a surge in Zika virus infections in the United States and its territories, particularly in Florida, Puerto Rico, and Texas. In Puerto Rico alone, there were 61 confirmed cases of GBS linked to Zika virus infection. The spread of Zika and its association with GBS have heightened the demand for effective therapies.

Furthermore, North America's advanced healthcare infrastructure and support for rare disease research have accelerated the development of GBS treatments. In 2020, the National Institutes of Health (NIH) allocated more than $1.5 billion for neurological disorder research, which includes funding for rare diseases like GBS. This strong financial backing and institutional support drive innovations in GBS treatments, expanding the availability of drugs for patients.

How Do Government Initiatives Shape the Market Landscape in Europe?

Europe is estimated to exhibit significant growth within the GBS drugs market during the forecast period. Europe has witnessed a rising incidence of autoimmune disorders, including Guillain-Barre Syndrome, which drives the demand for treatments like immunoglobulins. According to a 2022 report from the European Academy of Neurology (EAN), approximately 1 to 2 individuals per 100,000 are diagnosed with GBS annually across Europe, translating to nearly 10,000 new cases each year. This increasing incidence boosts the demand for effective therapies.

Europe has seen a correlation between influenza outbreaks and the onset of GBS, prompting increased use of immunoglobulins and other therapies. According to the European Centre for Disease Prevention and Control (ECDC), influenza vaccines in 2021-2022 were linked to a 7% rise in GBS cases in some regions due to complications. The strong connection between influenza and GBS drives the need for accessible GBS treatments, particularly during the flu season.

Furthermore, European governments have prioritized rare diseases like GBS through various initiatives, driving the research and availability of treatments. The European Union's Orphan Drug Regulation has incentivized drug development for rare diseases since 2000. As of 2022, over 200 orphan medicinal products have been approved for rare diseases, including GBS, providing a significant boost to the GBS drugs market.

Competitive Landscape

The Guillain barre syndrome drugs market's competitive landscape is characterized by a varied range of large pharmaceutical companies and smaller specialized firms focusing on rare neurological disorders.

Some of the prominent players operating in the guillain barre syndrome drugs market include:

Grifols S.A.

CSL Behring

Shire (now part of Takeda Pharmaceutical Company)

Octapharma AG

Nihon Pharmaceutical Co., Ltd.

Akari Therapeutics, Plc

Hansa Biopharma AB

Biotest AG

China Biologic Products Holdings, Inc.

Kedrion Biopharma Inc.

Latest Developments

In July 2023, Grifols, a global leader in immunoglobulin therapies, announced a strategic partnership with the European Neurological Society to advance research on Guillain-Barre Syndrome (GBS) treatments. This collaboration aims to support clinical trials focusing on the efficacy of intravenous immunoglobulins (IVIg) in managing GBS symptoms and improving patient outcomes. The partnership is expected to accelerate the availability of enhanced GBS therapies across Europe.

In March 2022, Octapharma, a leading pharmaceutical company, launched a new clinical trial for its human plasma-derived immunoglobulin product in Europe, targeting patients with GBS. This trial is focused on evaluating the long-term benefits of IVIg treatments in reducing recovery time for GBS patients. Octapharma's trial is part of its broader strategy to expand its GBS drug portfolio in Europe.

Guillain Barre Syndrome Drugs Market, By Category

• Treatment Type:
• Intravenous Immunoglobulin
• Plasma Exchange
• Supportive Care
• Drug Class:
• Immunoglobulins
• Anticonvulsants
• Antidepressants
• NSAIDs
• Opioids
• Others
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Guillain-Barre Syndrome Drugs Competitive Market, By Drug Class

• Immunoglobulins
• Anticonvulsants
• Antidepressants
• NSAIDs
• Opioids
• Others

5. Guillain-Barre Syndrome Drugs Competitive Market, By Treatment Type

• Intravenous Immunoglobulin
• Plasma Exchange
• Supportive Care

6. Guillain-Barre Syndrome Drugs Competitive Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Grifols S.A.
• CSL Behring
• Shire (now part of Takeda Pharmaceutical Company)
• Octapharma AG
• Nihon Pharmaceutical Co., Ltd.
• Akari Therapeutics, Plc
• Hansa Biopharma AB
• Biotest AG
• China Biologic Products Holdings, Inc.
• Kedrion Biopharma Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References